Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
CLYM

Climb Bio, Inc.

CLYM

NASDAQ·Healthcare·Biotechnology·Mkt cap $888.7M

$15.52

▲ +6.37%

P/E

-18.70

Mkt Cap

$888.7M

52-Wk Range

$1.54–$18.33

52-Week Range

$1.54 - $18.33

P/E

-18.70

Fwd P/E

-19.55

Beta

0.07

Div Yield

0.00%

Avg Vol

1.3M

Shares Out

68.2M

Mkt Cap

$888.7M

Price action

Price chart

Up 528.3% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Mechanism of action targeting CD19 B cells with potential for broad autoimmune applications
  • Clinical development progress in multiple high-prevalence autoimmune indications
  • Focused development strategy in underserved patient populations with limited treatment options
  • Experienced management team with biotechnology and immunology expertise
▼

Bear Case

1 risk

  • Low volatility (beta 0.1).

Growth

Stable outlook

Advancement of budoprutug through clinical trials across multiple autoimmune indications

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+44.1% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 5, 2026

“
Q3 26 RECAP

AUG 6, 2026

Reported EPS of -$0.18 vs -$0.21 consensus (+14.0% surprise).

EPS beat +14.0%

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+14.0%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

8 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

8

100%

Hold

0%

Sell

0%

Median Price Target

$40.00

▲ +157.7% vs $15.52

Low $40.00
Median $40.00
High $40.00

Latest: B. Riley · Sep 4, 2026

1 analyst covering

View full analyst page →

vs Industry

How CLYM stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.